BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34402131)

  • 1. Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor.
    Hwang KT; Suh YJ; Park CH; Lee YJ; Kim JY; Jung JH; Kim S; Min J;
    Oncologist; 2021 Nov; 26(11):e1939-e1950. PubMed ID: 34402131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.
    Hwang KT; Kim EK; Jung SH; Lee ES; Kim SI; Lee S; Park HK; Kim J; Oh S; Kim YA;
    Breast Cancer Res Treat; 2018 Jun; 169(2):311-322. PubMed ID: 29383628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
    J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen Initiation After Ductal Carcinoma In Situ.
    Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
    Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Progesterone Receptor Matter in the Risk of Recurrence for Patients With Ductal Carcinoma in Situ?
    Chaudhary LN; Jawa Z; Hanif A; Szabo A; Kamaraju S; Cheng YC; Chitambar CR
    WMJ; 2018 Jun; 117(2):62-67. PubMed ID: 30048574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
    Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
    J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma
    Thorat MA; Levey PM; Jones JL; Pinder SE; Bundred NJ; Fentiman IS; Cuzick J
    Clin Cancer Res; 2021 May; 27(10):2861-2867. PubMed ID: 33727261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term prognostic effect of hormone receptor subtype on breast cancer.
    Hwang KT; Kim J; Jung J; Kim BH; Park JH; Jeon SY; Hwang KR; Roh EY; Park JH; Kim SJ
    Breast Cancer Res Treat; 2020 Jan; 179(1):139-151. PubMed ID: 31595365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
    Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
    Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
    Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
    Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annual cost-savings with the implementation of estrogen-receptor-only testing on Ductal Carcinoma in Situ specimens.
    Gellings JA; Cortina CS; Jorns JM; Johnson MK; Huang CC; Kong AL
    Am J Surg; 2023 Feb; 225(2):304-308. PubMed ID: 36283883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.
    Barnes NL; Boland GP; Davenport A; Knox WF; Bundred NJ
    Br J Surg; 2005 Apr; 92(4):429-34. PubMed ID: 15736216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
    Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
    Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.